431063-04-6

Basic information

• Product Name: 3-hexadecyloxy-2-(5'-hexenyloxy)-sn-1-trityloxypropane
• Synonyms: 3-hexadecyloxy-2-(5'-hexenyloxy)-sn-1-trityloxypropane
• CAS NO: 431063-04-6
• Molecular Weight: 640.99
• Mol File: 431063-04-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-hexadecyloxy-2-(5'-hexenyloxy)-sn-1-trityloxypropane(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hexadecyloxy-2-(5'-hexenyloxy)-sn-1-trityloxypropane(431063-04-6)
• EPA Substance Registry System: 3-hexadecyloxy-2-(5'-hexenyloxy)-sn-1-trityloxypropane(431063-04-6)

Safety Data

• Hazardous Substances Data: 431063-04-6(Hazardous Substances Data)

Upstream product

• 92471-46-0 (R)-3-(1-hexadecyloxy)-1-(trityloxy)propan-2-ol 
• 64818-36-6 5-hexenyl methanesulfonate 
• 2695-47-8 6-Bromo-1-hexene 

Downstream Products

• 431063-02-4 (S)-1-hexadecyl-2-(5'-hexenyl)-sn-glycerol 
• 76-84-6 triphenylmethyl alcohol 
• 1221231-22-6 1-hexadecyl-2-(4-carboxy)butyl-3-sn-glycerol 

Relevant articles and documents

OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF

Novel oxidized thiophospholipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. Exemplary oxidized thiophospholipid according to embodiments described herein have the formula: (I) wherein X1, X2, A1, A2, B', B'', D' and D'' are as described herein.

Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis

Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.